S.E.A. Medical Secures $3 Million in Series B Financing from JK&B Capital
Healthtech company makes strides towards developing medical devices designed to catch life-threatening IV drug errors before they harm patients
Articles by Herina Ayot
Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
Editor’s Note February 21, 2012
In this week’s Sentinel: Peter Winter continues to bring us financings and developments in the global diagnostics business. BIO CEO & Investor Conference 2012, held […]
March 8 – 9, 2012 Korea Investor Conference
Shilla Hotel Seoul, Korea The 6th annual Citi Korea Investor Conference has evolved into one of the premier corporate access events in Korea. With over […]
Grant Thornton to Sponsor a Workshop on Funding Strategies for Life Sciences Companies
Research indicates that the financial crisis has led to a shift in the popularity, focus, and types of deals that are being done.
February 27-28 2012 Star Ratings Symposium
Star Ratings Symposium February 27-28 2012 Crowne Plaza Anaheim Resort, Anaheim, CA How would your rank your strategy for optimizing CMS’s 5-Star Quality Rating […]
Editor’s Note December 27, 2012
With a new year upon us, we are reminded of the year that is now coming to a close. 2011 has brought some amazing advancements […]
A New Era In Medical Devices Provides Critical Information in Real Time
The internet has ushered in a new era in Medical Devices as they begin to provide connectivity and communications to the health system to monitor the patient and provide critical clinical information.
Thermalin Diabetes Follows the “Coulter Process” And Addresses Significant Needs in the Insulin Market
Thermalin’s therapeutic proteins will address medical needs related to diabetes and its complications.
Anavex Life Sciences Challenges the Basic Assumptions In Treating Alzheimer’s Disease
The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.